Suzhou Ribo moves to full ownership of subsidiary in share-swap deal
What's the deal? Suzhou Ribo Life Science has agreed to buy the remaining 49.71% stake in a key subsidiary, taking its ownership to 100% through a share swap with minority holders. The company will settle the deal by issuing 14,087,085 new shares — about 7.63% of its enlarged share capital.
Why now? The move is the second step in a tightening of control over the subsidiary, Azemidite. Ribo bought an additional 25.93% stake for US$9.63M in June, lifting its holding to 88.17%; that deal closed in July.
What's the endgame? Ribo, a Hong Kong-listed Chinese biomedical company, has described the subsidiary as supporting nucleic-acid manufacturing. Full ownership comes as Ribo advances its siRNA pipeline, including a recent European Phase I application for obesity candidate RBD3133.
What could go wrong? Because key minority holders — including Erik Selin Fastigheter AB and entities tied to executive director Dr. Gan — are connected persons under Hong Kong rules, the transaction counts as both discloseable and connected. It requires independent-shareholder approval at an extraordinary general meeting, with the connected parties barred from voting.
The share issuance would also dilute existing holders by about 7.6% on the enlarged count, adding to scrutiny of the terms.
The signal: The deal shows Ribo consolidating its supply chain as it pushes a clinical-stage pipeline forward, but the related-party structure and dilution make the governance process worth watching.
Read more: tipranks.com
Image credit: Generated with Gemini
